Fluclotizolam 0.5mg Pellets
€ 150,00 – € 990,00Price range: € 150,00 through € 990,00
Fluclotizolam Pellets are described as a laboratory research preparation associated with fluclotizolam, a synthetic thienotriazolodiazepine characterized by a fused thiophene-containing diazepine framework.
Raw Lab Chems identifies this pellet presentation exclusively for controlled chemical identification, chromatographic characterization, spectroscopic investigation, and analytical comparisons involving benzodiazepine-related research compounds.
The supplied information includes claims concerning ingredient purity, independent testing, batch traceability, and controlled manufacturing. These specifications require supporting batch-specific documentation before they can be considered verified.
The labeled pellet content should be distinguished from independently established content uniformity or certified reference-material status.
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
Fluclotizolam Pellets 0.5mg – Thienotriazolodiazepine Research Material
Product Overview
Fluclotizolam Pellets are described in the supplied information as a laboratory research preparation associated with fluclotizolam, a synthetic compound belonging to the thienotriazolodiazepine family.
The compound is structurally related to other thiophene-containing triazolodiazepine derivatives.
Its molecular framework provides a basis for analytical investigations involving structural comparison, chromatographic behavior, and spectroscopic characterization.
Raw Lab Chems presents the material exclusively within a Research Use Only framework.
The supplied source describes compressed pellets intended for controlled laboratory examination.
However, the stated presentation does not independently establish the actual chemical identity, purity, finished-unit composition, or content uniformity.
The source also characterizes the preparation as laboratory-grade and refers to independent analytical verification and controlled manufacturing conditions.
These descriptions remain supplier-provided claims until supported by documentation associated with the actual batch.
No clinical, therapeutic, diagnostic, dietary, or consumer-oriented application is represented by this description.
Chemical Identity & Classification
Fluclotizolam is described in the supplied source as a thienotriazolodiazepine derivative.
The compound contains a fused thiophene-associated diazepine framework and is distinguished from classical benzodiazepines by its heterocyclic ring arrangement.
The supplied source provides the following chemical-reference information:
- Common name: Fluclotizolam
- Reported systematic name: 2-Chloro-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
- Chemical classification: Thienotriazolodiazepine derivative
- Reported CAS Registry Number: 54123-15-8
- Reported molecular formula: C15H10ClFN4S
- Reported molecular weight: 332.78 g/mol
These identifiers are reproduced from the supplied information and do not independently verify the composition of the actual product.
The reported molecular formula and molecular weight require reconciliation. The formula C15H10ClFN4S corresponds to an approximate molecular mass of 332.78 g/mol, but the supplied systematic name and molecular formula should still be checked against an authoritative chemical identity record.
The source does not provide independent structural confirmation for the actual pellet ingredient.
It also does not establish whether the preparation contains the freebase or a particular salt form.
This distinction matters because chemical form can affect molecular weight, solubility, and other analytical characteristics.
Researchers seeking public chemical-reference information may consult PubChem and confirm that any selected database entry corresponds to the intended compound and chemical form.
Chemical & Physical Characteristics
The supplied product is described as compressed pellets.
No product-specific physical inspection record, pellet-dimension specification, excipient list, or formulation characterization report was provided.
The stated physical form therefore remains a source-provided description.
The thienotriazolodiazepine structure provides a framework for comparing chemical characteristics with those of related thiophene-containing benzodiazepine derivatives.
However, structural similarity does not establish identical physical properties, analytical behavior, stability, or impurity profiles.
The source references chromatographic separation and spectroscopic characterization as areas of laboratory investigation.
No verified melting point, quantitative solubility profile, particle-size distribution, crystalline polymorph, density, or hygroscopicity measurement was supplied.
The properties of the finished pellet preparation may also depend on additional formulation ingredients.
No verified excipient composition, binder specification, or content-uniformity dataset accompanied the supplied information.
The source recommends storage in a cool, dry place protected from light and suggests refrigeration at 2–8°C for longer-term stability.
No validated stability study, degradation profile, or experimentally established shelf-life specification accompanied this recommendation.
Researchers should distinguish general storage guidance from verified stability data associated with a particular batch.
Purity & Analytical Verification
The supplied description claims purity of at least 98%, characterized as typical and independently verified.
However, no actual batch-specific Certificate of Analysis, chromatogram, mass spectrum, NMR spectrum, or independent laboratory report was provided.
Accordingly, the stated purity threshold is not independently confirmed for the material described here.
The source identifies HPLC, GC-MS, and NMR spectroscopy as analytical techniques associated with thienotriazolodiazepine investigation.
Such methods may provide information concerning chemical identity, structural characteristics, impurity profiles, and analytical specificity.
However, naming an analytical technique does not establish that it was performed on the actual product.
An important distinction exists between the purity of the chemical ingredient and the composition of the finished pellet.
Even if ingredient purity were independently established, that finding would not by itself verify the labeled component amount, total unit composition, or content uniformity.
The source references forensic chemical identification and analytical detection in complex matrices as research topics.
These references describe possible analytical investigation areas rather than validated performance characteristics of the supplied material.
Any reported purity or identity result should be evaluated against the actual sample, method documentation, reference materials, and relevant analytical limitations.
No certified reference-material status or independently established purity specification is asserted.
Quality Control & Batch Integrity
The supplied source claims that individual batches undergo third-party testing and are supported by Certificates of Analysis available upon request.
It also describes batch traceability, verification of identity and purity, and manufacturing under ISO-compliant conditions.
No actual certificate, laboratory accreditation record, manufacturing audit, quality-system documentation, or batch-specific testing report accompanied these statements.
They therefore remain unverified supplier claims.
For reproducible laboratory investigation, useful documentation may include supplier identification, batch number, chemical identifier, receipt date, storage history, and available analytical findings.
For pellet preparations, the identity and purity of the named ingredient should be distinguished from the composition and consistency of the finished units.
The supplied information does not establish independently verified content uniformity, excipient composition, or quantitative accuracy of the labeled amount.
Where a material is described as suitable for reference-standard work, researchers should distinguish ordinary catalog material from a certified reference material.
The supplied information does not establish certified reference-material status, metrological traceability, or an assigned measurement uncertainty.
Claims of consistent purity, identity, formulation quality, or manufacturing compliance should be supported by actual analytical records rather than inferred from catalog terminology.
Safety, Handling & Laboratory Precautions
Fluclotizolam is described as a thienotriazolodiazepine derivative requiring appropriate institutional risk assessment and controlled laboratory handling.
Research personnel should consult applicable chemical-safety documentation and institutional procedures before receiving or examining the material.
Laboratory precautions should address access restrictions, protective equipment, contamination prevention, accidental exposure, environmental release, and chemical-waste disposal.
The compound’s structural relationship to benzodiazepine-related substances does not establish safety for human or veterinary exposure.
The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments.
Because the actual purity and pellet composition have not been independently confirmed, laboratory documentation should distinguish verified characteristics from supplier-provided statements.
The pellet presentation must not be interpreted as evidence of pharmaceutical suitability or authorization for personal use.
Any accidental exposure or contamination incident should be managed according to institutional emergency procedures.
Packaging, Labeling & Storage
The supplied source describes secure packaging, appropriate chemical labeling, and professional handling during transportation.
No packaging-validation study, verified container specification, or actual shipment-condition record accompanied these claims.
The source recommends cool, dry storage protected from light and suggests refrigeration at 2–8°C.
No validated stability data was provided to establish that this temperature range is necessary or sufficient for a particular shelf life.
The source also claims that shipping arrangements support regulatory compliance and safe transit.
No shipment classification, carrier documentation, or compliance record was supplied to substantiate those statements.
Laboratory inventory records should preserve the compound name, any available batch identifier, receipt details, and relevant storage observations.
The labeled pellet content should be recorded as a source-provided specification unless independently confirmed.
Where chemical form or formulation ingredients remain uncertain, the inventory record should preserve those uncertainties rather than assign unverified details.
Packaging and environmental requirements should be assessed using available safety documentation, relevant stability evidence, and institutional laboratory procedures.
Intended Research Use & Market Positioning
The supplied scientific context places fluclotizolam within analytical research involving thienotriazolodiazepine derivatives, chemical characterization, structural comparison, and forensic identification.
Its fused thiophene-containing framework provides a basis for examining distinctions among related benzodiazepine-associated chemical structures.
The source also references chromatographic separation, mass-spectrometric characterization, and spectroscopic investigation as areas of laboratory research.
These references describe analytical research contexts and do not establish any human-use application.
For comparative chemical-catalog research, Raw Lab Chems also lists Flubrotizolam Pellets and Flubrotizolam Blister.
These listings identify other named research materials but do not establish equivalent chemical identity, purity, formulation, or analytical characteristics.
The supplied Fluclotizolam Pellets catalog reference identifies the product presentation discussed here.
These references provide chemical-catalog context rather than evidence of certified reference-material status or interchangeability.
Ordering, Availability & Fulfillment
The supplied source describes worldwide shipping, discreet packaging, tracking, and transportation through compliant carriers.
No current inventory information, carrier record, destination-specific authorization, or verified shipment-performance documentation was provided.
Consequently, no specific availability, delivery, customs-clearance, or transportation-compliance guarantee is asserted.
Thienotriazolodiazepine derivatives may be subject to controlled-substance or analog legislation.
Institutional acquisition and transfer should therefore be assessed against the applicable laws governing the exact substance and chemical form involved.
Researchers and institutions should independently verify whether possession, importation, exportation, transportation, and laboratory investigation are authorized in their jurisdictions.
Research-only labeling does not establish an exemption from controlled-substance regulations.
Legal & Regulatory Disclaimer
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
Fluclotizolam is described as a thienotriazolodiazepine derivative whose legal classification may vary by jurisdiction.
Acquisition, possession, transfer, importation, exportation, storage, and laboratory investigation may be restricted or prohibited under applicable controlled-substance, analog, or other chemical regulations.
Researchers and institutions remain responsible for determining legal requirements and obtaining any necessary authorizations.
No medical approval, consumer-use authorization, universal legal status, or regulatory exemption is implied by this description.
| Quantity |
250 pellets ,500 pellets ,1000 pellets ,2000 pellets |
|---|
You must be logged in to post a review.

Reviews
There are no reviews yet.